ImmuPharma (LON:IMM) Shares Up 15.6% – Time to Buy?

ImmuPharma plc ( LON:IMM – Get Free Report ) shot up 15.6% on Friday . The company traded as high as GBX 4.

50 ($0.06) and last traded at GBX 4.16 ($0.



05). 9,739,506 shares traded hands during trading, a decline of 47% from the average session volume of 18,399,727 shares. The stock had previously closed at GBX 3.

60 ($0.04). ImmuPharma Stock Up 9.

3 % The business has a fifty day simple moving average of GBX 1.75 and a two-hundred day simple moving average of GBX 1.73.

The company has a market capitalization of £16.39 million, a price-to-earnings ratio of -393.60 and a beta of 1.

53. ImmuPharma Company Profile ( Get Free Report ) ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.

The lead program, P140 (LupuzorTM), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. Featured Stories Five stocks we like better than ImmuPharma Dividend Capture Strategy: What You Need to Know Bloom Energy: Powering the Future With Decentralized Energy What is a buyback in stocks? A comprehensive guide for investors Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul How is Compound Interest Calculated? Why Traders Are Buying the Dip on Johnson & Johnson Stock Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter .

.